ArticleAmerican journal of preventive cardiology2022

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and moderate to high likelihood of non-alcoholic fatty liver disease.

Peter P Toth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.